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Human serum will inhibit the specific uptake of N-acetylglucosamine-terminated glycoproteins by isolated 
rat hepatic sinusoidal cells. The serum inhibitors are not glycoproteins that bind to the hepatic mannose/N- 
acetylglucosamine receptor but have the properties of lectins which bind to mannose/N-acetylglucosamine- 
terminated glycoproteins. They can be isolated from serum by affinity chromatography. The predominant 
lectin, with a molecular mass of less than 35 kDa, will inhibit the sinusoidal cell uptake of glycoproteins 
in vitro. 
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1. INTRODUCTION 
The survival of glycoproteins in the circulation is 
determined by the terminal non-reducing sugar 
residues of their oligosaccharide moiety [ 11. Galac- 
tose-terminated glycoproteins are rapidly cleared 
from the blood by a galactose-specific receptor on 
hepatocytes and mannose- and N-acetylglucosa- 
mine-terminated glycoproteins are cleared from 
the blood by a Man/GlcNAc specific receptor on 
hepatic sinusoidal cells (review [2]). Human serum 
will inhibit the binding of galactose-terminated 
glycoproteins to the galactose-binding protein in 
an in vitro assay [3]. The inhibitors are galactose- 
terminated glycoproteins [4]. We show here that 
human serum also contains a lectin which will 
inhibit glycoprotein uptake by the hepatic Man/ 
GlcNAc receptor. 
were prepared by the modification of human oro- 
somucoid (Sigma, Poole), and were radioiodinated 
with carrier-free Na12?, to a specific activity of 
5-12&i/pg by a solid-phase enzymobead system 
(Bio-Rad, Richmond, CA) which uses immobilized 
lactoperoxidase and glucose oxidase [5]. Mannan 
was also iodinated by this method to a specific 
activity of l.S&i/pg. Male Sprague Dawley rats 
bred in the Comparative Biology Unit of the Royal 
Free Hospital School of Medicine were used. 
Hepatic sinusoidal and parenchymal cells were 
prepared by collagenase perfusion followed by dif- 
ferential centrifugation and centrifugal elutriation 
as in [S]. One fraction containing endothelial and 
Kupffer cells was collected from centrifugal elutria- 
tion by pooling the cells eluted between 13 and 
46 ml/min. 
2. MATERIALS AND METHODS 
Asialo-orosomucoid and agalacto-orosomucoid 
Abbreviations: Man, mannose; GlcNAc, N-acetylglu- 
cosamine; ASOR, asialo-orosomucoid; AGOR, agalacto- 
orosomucoid; HBSS, Hank’s balanced salt solution. 
Sinusoidal cells (5-10 x lo6 cells/ml) were sus- 
pended in glucose-free HBSS (500,ul) containing 
1251-AGOR with or without serum or other inhibi- 
tors. After varying lengths of time duplicate sam- 
ples (200,ul) were placed in 400-~1 microfuge tubes 
and centrifuged in a Beckman microfuge B for 
30 s. The supernate was removed by aspiration and 
the cell pellet was washed once with glucose-free 
HBSS. Radioactivity in the cell pellet was deter- 
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mined. Non-specific binding of AGOR, in the 
presence and absence of serum, was estimated by 
measuring binding in the presence of the inhibitor 
mannan (250pg/ml) in parallel tubes. 
Uptake of 1251-ASOR by parenchymal cells was 
determined as described above except that the cells 
(106/ml) were suspended in complete HBSS. Non- 
specific binding of ASOR was estimated using a 
lOO-fold excess of unlabelled ASOR. 
AGOR or mannan was coupled to activated CH- 
Sepharose4B (Pharmacia, Uppsala). Mannan 
(Sigma) was purified by Sephadex G-200 chromato- 
graphy before use. The binding of ligand to Sepha- 
rose was estimated by the addition of 1251-AGOR 
(3 x lo6 cpm) or ‘251-mannan (1.8 x 1O”cpm) to 
the coupling reaction mixture. AGOR-Sepharose 
bound approx. 5 mg AGOR/ml Sepharose, and 
mannan-Sepharose approx. 2 mg mannan/ml 
Sepharose. 
Human serum (6-12 ml), dialysed against glu- 
cose-free HBSS, was mixed with an equal column 
of 0.02 M Tris-HCl (pH 7.4), 40mM CaCl2, 
0.5 M NaCl, and incubated at 4°C with either 
AGOR-Sepharose (5 ml) or mannan-Sepharose 
(7.5 ml) suspended in 0.02 M Tris-HCI (pH 7.4), 
20 mM CaC12, 0.5 M NaCl (column buffer). After 
1 h the Sepharose suspension was loaded into a col- 
umn and washed with column buffer until the 
absorbance at 280nm of the eluate was less than 
0.01. The column was eluted with 0.2 M a-methyl 
mannoside (Sigma) in column buffer at room tem- 
perature and 6-ml fractions were collected. The 
fractions were dialyzed exhaustively against glu- 
cose-free HBSS to remove a-methyl mannoside 
before testing for inhibitory activity in the ligand 
cell uptake assay. 
3. RESULTS AND DISCUSSION 
The specific uptake of 1251-AGOR by isolated 
rat hepatic sinusoidal cells was inhibited by human 
and rat serum but not by albumin (up to 40 mg/ml) 
(fig. 1). All further experiments were carried out on 
human serum. Serum increased the apparent Kuptake 
of AGOR uptake but did not alter the apparent 
maximal uptake velocity indicating that inhibition 
was competitive (fig.2). Competitive inhibition of 
AGOR uptake could have been due to either a 
serum ligand, like ‘251-AGOR, binding to the cell 
receptor, or a serum lectin, like the cell receptor, 
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Fig. 1. Inhibition of specific AGOR uptake by dialyzed 
serum. Sinusoidal cells were incubated with “‘1-AGOR 
(O.Spg/ml) for 30 min at 37°C with increasing amounts 
of dialyzed serum or albumin (5% w/v in glucose-free 
HBSS). Representative of 4 experiments. 
binding to ‘251-AGOR. To distinguish between 
these mechanisms, we performed assays in which 
the concentrations of serum and AGOR were kept 
constant but the number of sinusoidal cells added 
were varied. We postulated that if inhibition was 
due to a serum ligand, the amount of inhibition 
observed would depend on the ratio of serum 
ligand to ‘251-AGOR and would be independent of 
cell receptor number (i.e., to cell number), whereas 
if it was due to a serum lectin, the amount of in- 
2- 
Fig.2. Double-reciprocal plot of AGOR uptake in the 
presence of serum. Sinusoidal cells were incubated for 
1Omin at 37°C with ‘Z51-AGOR (0%32,ug/ml) and 
serum. Representative of 3 experiments. 
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hibition would depend on the ratio of serum lectin 
to cell receptor and would therefore decrease as the 
number of cells in the assay was increased. Fig.3 
shows that the inhibition of 1251-AGOR uptake by 
serum decreased as the number of sinusoidal cells 
in the assay was increased. In the absence of serum 
the specific uptake of “‘1-AGOR expressed as 
ng/5 x lo6 cells, remained constant (not shown), 
showing that the decrease in percent inhibition was 
due to the presence of serum. Inhibition by glucose 
[5] remained constant as cell number increased 
(fig.3). The results indicated that the serum inhibi- 
tor(s) was competing with the sinusoidal cell 
Man/GlcNAc receptor for the binding of 1251- 
AGOR. In contrast, although serum also inhibited 
the uptake of ASOR by hepatocytes, the percent 
inhibition was independent of cell number (fig.4). 
This is consistent with the serum inhibitions of 
ASOR uptake being asialoglycoproteins [3]. 
As the inhibitors appeared to bind to AGOR and 
prevent it binding to the receptor, they should also 
bind to AGOR or mannan immobilized on Sepha- 
rose and be eluted by an appropriate monosac- 
charide. Fig.5 shows the result of passing serum 
through a column of mannan-Sepharose. There 
was an initial peak of inhibitory activity, repre- 
senting material passing unbound through the col- 
umn and indicating that the serum was not com- 
pletely stripped of inhibitory material. However, 
some inhibitory material was eluted by 0.2 M CY- 
methyl mannoside. The eluted fractions were com- 
bined, concentrated, and radioiodinated. Sepha- 
ol oI-_-__ 
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Fig.4. (a) Effect of serum on ASOR uptake by parenchy- 
ma1 cells. Parenchymal cells (106/ml) were incubated for 
45 min at 37°C with “‘I-ASOR (O.Spg/ml) and human 
serum (lo-70%). (b) Effect of increasing cell number on 
percent inhibition of ASOR uptake. Parenchymal cells 
(0.15-l x 106/ml) were incubated at 37°C for 45 min with 
‘Z51-ASOR (0.5 pg/ml) and serum (10%). Representative 
of 4 experiments. 
cry1 S200 chromatography of the radiolabelled 
material showed 3 peaks (fig.6) with a molecular 
mass greater than 68 kDa, and a broad peak of 
smaller material of molecular mass less than 
35 kDa. The first peak eluted in the void volume 
and therefore had a molecular mass of at least 
250 kDa. Sephacryl S200 chromatography of 
serum proteins eluted from AGOR-Sepharose 
gave the same profile (not shown). 
The effect of each Sephacryl S200 peak on the 
uptake of 1251-AGOR by sinusoidal cells was tested 
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Fig.3. Effect of increasing cell number on percent inhibi- 
tion of AGOR uptake. Sinusoidal cells (1.3-18.5 x 106/ 
ml) were incubated for 30min at 37°C with “‘I- 
AGOR (OSpg/ml) and 10% serum or 200 mg% glucose. 
Representative of 2 experiments. 
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Fig.5. Affinity chromatography of serum on mannan- 
Sepharose. Each fraction was dialyzed against glucose- 
free HBSS and tested for inhibitory activity by incubating 
with sinusoidal cells for 30 min at 37°C with “‘1-AGOR 
(0.5pg/ml). 
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Fig.6. Sephacryl S-200 chromatography of proteins 
eluted from mannan-Sepharose. Column (2.5 x 90 cm) 
eluted with 0.02M Tris-HCl (pH 7.4), 1 mM CaC12, 
0.5 M NaCl. 
after unlabelled proteins eluted from mannan- 
Sepharose were mixed with a trace of 1251-labelled 
material and separated on Sephacryl S200. The 
fractions from each peak were combined, concen- 
trated using 30% polyethylene glycol (w/v), dia- 
lyzed against 0.9% saline, and adjusted to a final 
volume of 5 ml. Table 1 shows the amount of pro- 
tein (estimated by a modified Lowry procedure [6]) 
in each peak that was obtained from 40 ml serum. 
Only the smaller molecular mass material (peak 4), 
Table I 
Inhibition of sinusoidal cell uptake of 1251-AGOR by 
Sephacryl S-200 fractions 
Peaka Total protein (mg)b Inhibition’ 
1 0.28 9 
2 1.42 4 
3 0.82 33 
4 2.55 73 
a See fig.6 for peak assignment 
b Isolated from 40 ml serum by mannan affinity chroma- 
tography 
’ Sinusoidal cells incubated for 30 min at 37°C with rz51- 
AGOR (0.5pg/ml) and 300~1 concentrated Sephacryl 
S-200 fractions (see section 2). Mean of 2 experiments 
which accounted for approximately half of the 
protein eluted from the mannan column, caused 
inhibition (table 1). Since smaller amounts of the 
larger proteins were used in the inhibition assay, it 
is possible that these would also inhibit AGOR up- 
take at higher concentrations. 
A mannan-binding protein has been isolated 
from rabbit serum [7] with a molecular mass of 
about 500 kDa, composed of subunits of 29 kDa. 
It is immunologically identical to the mannan- 
binding protein isolated from whole rabbit liver 
[8]. The protein of molecular mass >250 kDa that 
we isolated may be similar to the rabbit serum lec- 
tin. However, in contrast to the rabbit serum 
lectin, our data indicate that in human serum the 
predominant lectin has a molecular mass ~35 kDa. 
It is intriguing to speculate on the physiological 
role of these lectins in serum. Conceivably, the 
lectins interact with potentially toxic mannose- 
terminated enzymes such as lysosomal hydrolases 
which escape from cells into the serum. They could 
act in an analogous way to cur-antitrypsin and the 
other components of the serum anti-protease sys- 
tem. The exact nature of these serum lectins with 
Man/GlcNAc specificity needs to be defined more 
clearly. 
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